EU4Health call to support the development of novel antivirals (HERA) - CP-g-24-105

Details

Status

Open

Reference

EU4H-2024-PJ-01-4

Publication date

23 May 2024

Opening date

23 May 2024

Deadline model

Single-stage

Deadline date

5 September 2024, 17:00 (CEST)

Programme Sector

Health

Programme

EU4Health

Tags

AWP

EUFunded

Health preparedness

Proposals

Description

This action aims to diversify and advance the pipeline of BSA candidates. More specifically, it will support the development and further characterisation of broad-spectrum antivirals targeting identified HERA priority viral families, which largely can be divided among respiratory RNA viral families, such as Paramyxo-, Orthomyxo and Coronaviridae, as well as those targeting viral families known for causing viral haemorrhagic fever (VHF), such as Arena-, Bunya-, Flavi-, Filoviridae. The action aims to identify a potent BSA candidate, in order to advance its clinical development. A robust pipeline should contain multiple BSA candidates for each viral family that are developed in parallel. When selecting the BSA candidate, attention will be paid to the complementarity with existing Horizon Europe projects.

The proposal would need to cover early safety and efficacy trials for testing new or improved anti-viral therapeutics, with a clear regulatory and clinical pathway, including first in humans.

Innovative delivery systems and suitable safety profiles for broad use should be considered when possible as well as the application of novel approaches and widely applicable workflows (e.g. artificial intelligence) for rapid and reliable identification of broad-spectrum anti-viral therapeutics.

Read more and apply on the Funding and Tenders Portal.

Paket Tender

Paket Tender

(BE) Poziv za podršku razvoju novih antivirusnih lijekova (HERA) - CP-g-24-105-EU4Health

Više o naručiocu